- Home
- » Tags
- » Inotuzumab ozogamicin
Top View
- (INN) for Biological and Biotechnological Substances
- Novel Immunotherapies and Their Role in the Treatment of Acute Lymphoblastic Leukemia
- Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
- Download a List of Pediatric Oncology and Sickle Cell Studies
- Practice Corner COG Feature of the Quarter APN Updates
- (12) United States Patent (10) Patent No.: US 9.260,393 B2 Becker Et Al
- Besponsa, INN-Inotuzumab Ozogamicin
- The Oncology Market for Antibody–Drug Conjugates
- Assessment of Clinical Immunogenicity of Inotuzumab Ozogamicin In
- Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
- Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
- Besponsa™ (Inotuzumab Ozogamicin)
- Novel Immunotherapies for Adult Patients with B-Lineage Acute Lymphoblastic Leukemia Guoqing Wei, Jiasheng Wang, He Huang and Yanmin Zhao*
- Advances in Llm
- Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients with Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia 2015-0870
- Mylotarg, INN-Gemtuzumab Ozogamicin
- Incorporating Antibodies Into Treatment Strategies for Acute Lymphoblastic Leukemia
- Acquired Resistance to Antibody-Drug Conjugates
- Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: a Systematic Review
- Advances in Hematology & Oncology Volume 10, Issue 4 April 2012 April 4 Issue 10, Volume Oncology & Hematology in Advances Clinical
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- Customs Tariff - Schedule Xxi - 1
- Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
- Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
- Oncology Therapy for the Generalist
- CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
- Inotuzumab Ozogamicin
- Cost by Outcomes Analysis of Blinatumomab and Inotuzumab
- Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (ALL)
- Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody–Drug Conjugates in Oncology
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- A Value-Based Pricing Study of Inotuzumab Ozogamicin for B-Cell Precursor Acute Lymphoblastic Leukemia (B-Cell All) in the United States
- Game Changers in Pediatric Cancer Jane De Lartigue, Phd
- Clinical Trial Update on Bispecific Antibodies, Antibody-Drug
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- INO-VATE (Inotuzumab Ozogamicin Trial to Investigate Tolerability And
- BESPONSA (Inotuzumab Ozogamicin) RATIONALE FOR
- Clinical Roundtable Monograph
- (INN) for Biological and Biotechnological Substances
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Working Minutes of the Ephmra Classification Committee
- Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia T ⁎ Kirk D
- Blincyto® (Blinatumomab) to Include Approval of Tafinlar® (Dabrafenib)
- 761040Orig1s000
- Design and Efficacy of Antibody Drug Conjugates in Oncology
- Antibody–Drug Conjugates
- Besponsa (Inotuzumab Ozogamicin) (Intravenous) Document Number: IC-0317 Last Review Date: 10/30/2018 Date of Origin: 09/19/2017 Dates Reviewed: 09/2017, 11/2018
- Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Inotuzumab Ozogamicin As Frontline Therapy for Adults Wi
- Recent Developments in Immunotherapy for Acute Lymphoblastic Leukemia
- Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016
- DRUG NAME: Inotuzumab Ozogamicin
- Antibody–Drug Conjugates: a Comprehensive Review Puregmaa Khongorzul1, Cai Jia Ling1, Farhan Ullah Khan2, Awais Ullah Ihsan3, and Juan Zhang1
- Inotuzumab Ozogamicin in Clinical Development for Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma Amandeep Aujla1, Ravijot Aujla2 and Delong Liu1,3*
- Antibodies to Watch in 2018